Due to the rapidly evolving landscape of targeted therapies, there is an unmet need for
comprehensive molecular profiling to guide treatment decisions for lymphoma patients …

Background: Due to the rapidly evolving landscape of targeted therapies, there is an unmet
need for comprehensive molecular profiling to guide treatment decisions for patients with …

Introduction Due to the rapidly evolving landscape of targeted therapies, there is an unmet
need for comprehensive molecular profiling to guide treatment decisions for patients with …

Aims Genomic sequencing of lymphomas is under-represented in routine clinical testing
despite having prognostic and predictive value. Clinical implementation is challenging due …

CME Accreditation Statement: This activity (“JMD 2018 CME Program in Molecular
Diagnostics”) has been planned and implemented in accordance with the accreditation …

Introduction: Genome-and transcriptome-wide analyses continue to enhance our
understanding of the molecular pathogenesis of cancer. In lymphomas, this has enabled the …

Successful treatment of relapsed/refractory and rare subtypes of lymphomas remains a
therapeutic challenge. Though the use of tumor profiling is increasing, little is described …

Background: Current diagnostic criteria for mature B-cell tumors require a combination of
histopathological, immunophenotypic, cytogenetic, and genetic evaluations on tissue biopsy …

Authors 1-3: Contributed equally to this work Authors 8-9: Shared last author Background
Genetic material from aggressive B-cell lymphoma is typified by recurrent multiple somatic …

Introduction: Few studies provide next-generation sequencing (NGS) based, clinical
genomic profiling across lymphoma subtypes using tumor and matched normal samples to …